Pioglitazone: Reviewed and Renewed

Abdul-Ghani M Puckett C Adam J , et al. Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT. Diabetes Care. 2021;44(2):433-439. doi:10.2337/dc20-0978

Alam F Islam A Mohamed M , et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):5389. doi:10.1038/s41598-019-41854-2

American Diabetes Association. Standards of medical care in diabetes - 2021. Diabetes Care. 2021;44(1):S111-S124.

Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fund Clin Pharmacol. 2009;23:675-679.

Capoccia K. The resurrection of pioglitazone: case reports of low-dose pioglitazone in type 2 diabetes. Poster presented at: AACP Global Conference on Clinical Pharmacy; October 20-23, 2018; Seattle, WA.

Capoccia K Odegard P. Thiazolidinediones. In: White JR , ed. 2021 Guide to Medications for the Treatment of Diabetes Mellitus. American Diabetes Association; 2021.

Davidson MB Pan D. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract. 2018;135:102-110.

DeFronzo R Inzucchi S Abdul-Ghani M , et al. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16(2):133-143.

Lee M Saver JL Liao HW Lin CH Ovbiagele B. Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke. 2017;48:388-393.

Mills EP Brown KPD Smith JD Vang PW Trotta K. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. Ther Adv Endocrinol Metab. 2018;9(1):15-28.